FDA Issues Early Communication About Ongoing Safety Review of Weight Loss Drug Orlistat
published online 22 September 2009.
The US Food and Drug Administration (FDA) announced that it is reviewing new safety information regarding reports of liver-related adverse events in patients taking orlistat. Orlistat is marketed in the United States as a prescription product, Xenical, and as an over-the-counter (OTC) product, Alli.
Richard Peek and K. Rajender Reddy, Section Editors
PREVIEW